Method and means for the early detection and diagnosis of certain types of cancers

• US 4,150,149 A
• Filed: 11/29/1976
• Issued: 04/17/1979
• Est. Priority Date: 11/29/1976
• Status: Expired due to Term

• Current Assignee: Professional Staff Association of The Los Angeles County Harbor General Hospital
• Original Assignee: Professional Staff Association of The Los Angeles County Harbor General Hospital
• Inventors: Odell, William D., Wolfsen, Ada R.
• Primary Examiner(s): Padgett, Benjamin R.
• Assistant Examiner(s): Nucker, Christine M.
• Application Number:
  US05/745,672
• Time in Patent Office: 869 Days
• Field of Search: 23/230 B, 23/259 R, 424/1, 424/1.5, 424/12, 206/569
• US Class Current: 436/542
• CPC Class Codes: G01N 2333/5751 Corticotropin releasing factor [CRF] (Urotensin)
• CPC Class Codes: G01N 2333/5757 Vasoactive intestinal peptide [VIP] or related peptides
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: Y10S 436/804 Radioisotope, e.g. radioimmunoassay
• CPC Class Codes: Y10S 436/808 Automated or kit
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 436/817 Steroids or hormones

Abstract

This invention is directed to a method and means for the early detection of a wide variety of cancers, in humans, which method and means consists of the assay and development of a pattern or fingerprint of severally biologically inert, or inactive polypeptides (or perhaps biologically active peptides) in the blood of humans, e.g.: big-ACTH (big-Adrenocorticotropin Hormone), big-βMSH (big-beta melanocyte-stimulating Hormone), the alpha chain of the glycopeptide hormones, the measurement of the arginine vasotocin (AVT), an analogue of Arginine vasopressin, (AVP) (or the combined measurement of AVP and AVT). The values obtained by the assays of each of the foregoing polypeptids is then compared with the individual values and patterns found in humans. If any one of the polypeptide values is elevated above the upper end of the normal values, a carcinoma from some tumor site is suspected; also from the pattern of elevations in one or more peptides, a specific type of cancer may be suspected. The tumor site can then be readily localized. The level of detectability of a carcinoma from a variety of tumor sites, by means of this procedure approaches 100%. Since evidence of these biologically inactive prohormones, fragments and analogues of hormones precedes clinically recognizable ectopic hormone production by months or years, an early, reliably detection system for carcinoma cancers is set forth herein. Assays of each of the polypeptides is performed by means of radioimmunoassay coupled with radioreceptorassay or bioassay, where necessary.

Claims

1. A kit for the screening of cancer of certain tumors and histological types in humans, which includes the combination of:

(i) means, for quantifying the level of a peptide selected from the group consisting of big-ACTH (big-Adrenocorticotropen Hormone), ACTH, and 1-39 amino acid ACTH in human serum;

(ii) means, for quantifying the level of big-β

MSH (big-β

melanocyte-stimulating hormone) peptide in human serum;

(iii) means, for quantifying the level of the alpha chain of glycopeptide hormone in human serum; and

(iv) means, for quantifying the level of the peptide selected from the group consisting of Argenine vasotocin (AVT) and Argenine vasopressin (AVP) plus Argenine vasotocin (AVT) in human serum, each of said means for each of said peptides including in containers a known quantity of radioactive peptide of each type to be assayed, a binding agent specific for the binding of the peptide of the type to be assayed, and a known quantity of the peptide to be assayed for preparation of a standard curve.

2. The kit of claim 1, which further includes containers of buffer for the buffering of human serum.

3. The kit of claim 1 in which the means for quantifying big-ACTH further includes in containers:

a known quantity of reagent for separating antibody bound radioactive ACTH from free radioactive ACTH for measurement of the level of ACTH in said human serum.

4. The kit of claim 3 which further includes containers of buffer for the buffering of human serum.

5. The kit of claim 1, in which the means for quantifying big-ACTH further includes in containers:

a known quantity of reagent for separating antibody bound radioactive ACTH from free radioactive ACTH for measurement of the level of ACTH in said human serum;

a known quantity of tissue receptor specific for the binding of 1-39 amino acid ACTH; and

a known quantity of reagent for separating antibody bound radioactive 1-39 amino acid ACTH from free radioactive 1-39 amino acid ACTH for measurement of 1-39 amino acid ACTH.

6. The kit of claim 5 which further includes containers of buffer for the buffering of human serum.

7. The kit of claim 1 which further includes in containers:

a known quantity of reagent for separating antibody bound radioactive hβ

MSH from free radioactive hβ

MSH for measurement of big-hβ

MSH in humans.

8. The kit of claim 7 which further includes:

containers of buffer for the buffering of human serum.

9. The kit of claim 1 which further includes in containers:

a known quantity of reagent for separating antibody bound radioactive α

chain of the glycopeptide hormone from free radioactive α

chain of the glycopeptide hormone.

10. The kit of claim 9 which further includes

containers of buffer for the buffering of human serum.

11. The kit of claim 1, in which the means for quantifying the level of AVP plus AVT, includes in containers:

a known quantity of radioactive Argenine vasopressin (AVP);

a known quantity of antibody specific for the binding of both AVP and AVT;

a known quantity of AVP and AVT for preparation of standard curves; and

a known quantity of reagent for separating antibody bound radioactive AVP and AVT from free radioactive AVP and AVT for measurement of the level of AVP and AVT in human serum.

12. The kit of claim 11, which further includes:

means for quantifying the level of AVT plus AVP; and

means for quantifying the level of AVP, to thereby enable quantification of AVT by difference.

13. The kit of claim 1 in which the means for quantifying big-ACTH includes in containers:

a known quantity of reagent for separating antibody bound radioactive ACTH from free radioactive ACTH for measurement of the level of ACTH in said human serum; and

means for measuring the level of 1-39 amino acid ACTH whereby the big-ACTH level is calculated;

the means for quantifying big-h β

MSH includes in containers;

a known quantity of reagent for separating antibody bound radioactive h β

MSH from free radioactive h β

MSH for measurement of big-h β

MSH in humans;

the means for quantifying the α

chain of the glycopeptide hormone includes in containers;

a known quantity of reagent for separating antibody bound radioactive α

chain of the glycopeptide hormone from free radioactive α

chain of the glycopeptide hormone; and

the means for quantifying the level of AVP plus AVT, includes in containers;

a known quantity of reagent for separating antibody bound radioactive AVP and AVT from free radioactive AVP and AVT for measurement of the level of AVP and AVT in human serum.

14. The kit of claim 13 which further includes

containers of buffer for the buffering of human serum.

15. The kit of claim 13 which includes in addition:

means for quantifying the level of AVP to thereby enable quantification of AVT by difference.

19. The method of claim 10 which includes quantifying the level of big-β

melanocyte-stimulating hormone (big-h β

MSH) by;

A;

adding, to a measured quantity of human serum,

(a) buffering ions to buffer said serum;

(b) radioactive h β

MSH peptide selected from the group of big-h β

MSH and small-h β

MSH peptide, in an amount which will give a measurable counting rate of either antibody bound or free radioactivity after reaction equilibrium has been reached as set forth in Step B below; and

(c) an antibody in sufficient quantity to bind a significant quantity of said selected radioactive h-β

MSH peptide in the absence of any of the non-reactive big-h β

MSH peptide to be measured;

B;

allowing reaction of both the big h β

MSH peptide, to be measured, and said selected radioactive h β

MSH peptide, with said antibody to proceed substantially to equilibrium to thereby produce an antibody bound radioactive big-h β

MSH peptide;

C;

separating said antibody bound radioactive big-h β

MSH peptide, to be measured, from said free radioactive big-h β

MSH peptide;

D;

measuring the quantity of radioactive big-h β

MSH peptide selected from antibody bound radioactive big-h β

MSH peptide and free radioactive big-β

MSH peptide;

E;

preparing a standard curve with known amounts of the big-h β

MSH peptide to be measured; and

F;

correlating the quantity of radioactive big-h β

MSH peptide measured with a known amount of said big-β

MSH peptide read from said standard curve.

23. A method of screening for cancer of certain tumor and histological types in humans, which includes the combination of the following steps:

(i) measuring the level of big-ACTH (big-Adrenocorticotropin Hormone) peptide in human serum by radioimmunoassay of ACTH, assay of 1-39 amino acid ACTH and calculating the difference as big ACTH;

(ii) measuring by radioimmunoassay, the level of big β

MSH (big-melanocyte-stimulating hormone) peptide in human serum;

(iii) measuring by radioimmunoassay, the level of the α

chain of glycopeptide hormone in human serum;

(iv) measuring by radioimmunoassay, the level of the peptide selected from the group consisting of argenine vasotocin (AVT) and argenine vasopressin (AVP plus argenine vasotocin (AVT) in human serum, the steps (i) through (iv) being performed in any sequence employing the kit of claim 1;

each radioimmunoassay including a measurement of the free or bound radioactive peptide; and

comparing the level of each of said peptides with normal values circulating in the blood of humans to determine the elevation, if any, of any of said peptides.

16. A method of screening for carcinoma of certain tumor and histological types in humans, which includes the combination of the following steps:

(i) measuring the level of big-ACTH (big-Adrenocorticotropin Hormone) peptide in human serum by radioimmunoassay of ACTH, assay of 1-39 amino acid ACTH, and calculating the difference as big-ACTH;

(ii) measuring the level of big-β

MSH (big-β

melanocyte-stimulating hormone) peptide in human serum by radioimmunoassay;

(iii) measuring the level of the α

chain of glycopeptide hormone in human serum by radioimmunoassay;

(iv) measuring the level of the peptide selected from the group consisting of argenine vasotocin (AVT) and argenine vasopressin (AVP) plus argenine vasotocin (AVT) in human serum by radioimmunoassay the steps (i) through (iv) being performable in any sequence;

each radioimmunoassay including a measurement of the free or bound radioactive peptide; and

comparing the level of each of said peptides with normal values circulating in the blood of humans to determine the elevation, if any, of any of said peptides.

17. The method of claim 16 in which the assay of 1-39 amino acid ACTH is performed by a tissue receptor assay.

18. The method of claim 16 which includes quantifying the level of big-Adrenocorticotropin Hormone (big-ACTH) by:

A. adding, to a measured quantity of human serum,

(a) buffering ions to buffer said serum;

(b) radioactive ACTH, in an amount which will give a measurable counting rate of either antibody bound or free radioactivity after reaction equilibrium has been reached as set forth in Step B below; and

(c) an antibody in sufficient quantity to bind a significant quantity of said radioactive ACTH in the absence of any of the nonradioactive ACTH to be measured;

B. allowing reaction of both ACTH, to be measured, and said radioactive ACTH, with said antibody to proceed substantially to equilibrium to thereby produce an antibody bound radioactive ACTH;

C. separating said antibody bound radioactive ACTH, to be measured, from said free radioactive ACTH;

D. measuring the quantity of radioactive ACTH selected from antibody bound radioactive ACTH and free radioactive ACTH;

E. preparing a standard curve with known amounts of the ACTH to be measured;

F. correlating the quantity of radioactive ACTH measured with a known amount of said ACTH read from said standard curve;

G. quantifying the level of 1-39 amino acid ACTH; and

H. determining the quantity of big ACTH by substracting the measured quantity of 1-39 amino acid ACTH from the quantity of ACTH determined by the procedure of Steps A-F.

20. The method of claim 16 which includes quantifying the level of α

chain of the glycopeptide hormone by;

A;

adding, to a measured quantity of human serum

(a) buffering ions to buffer said serum;

(b) radioactive α

chain of the glycopeptide hormone, in an amount which will give a measurable counting rate of either antibody bound or free radioactivity after reaction equilibrium has been reached as set forth in Step B below; and

(c) an antibody in sufficient quantity to bind a significant quantity of said radioactive α

chain of the glycopeptide hormone in the absence of any of the non-radioactive α

chain of the glycopeptide hormone to be measured;

C;

separating said antibody bound radioactive α

chain of the glycopeptide hormone, to be measured, from said free radioactive chain of the glycopeptide hormone.

D;

measuring the quantity of radioactive α

chain of the glycopeptide hormone selected from antibody bound radioactive α

chain of the glycopeptide hormone and free radioactive α

chain of the glycopeptide hormone;

E;

preparing a standard curve with known amounts of the α

chain of the glycopeptide hormone; and

F;

correlating the quantity of radioactive α

chain of the glycopeptide hormone measured with a known amount of said α

chain of the glycopeptide hormone read from said standard curve.

21. The method of claim 16 which includes quantifying the level of arginine vasoticin plus arginine vasopressin (AVT+AVP) by:

A;

adding, to a measured quantity of human serum

(a) buffering ions to buffer said serum;

(b) radioactive AVP+AVT, in an amount which will give a measurable counting rate of either antibody bound or free radioactivity after reaction equilibrium has been reached as set forth in Step B below; and

(c) an antibody in sufficient quantity to bind a significant quantity of said radioactive AVP+AVT in the absence of any of the non-radioactive AVP+AVT to be measured;

B;

allowing reaction of both AVP+AVT, to be measured, and said radioactive AVP+AVT, with said antibody to proceed substantially to equilibrium to thereby produce an antibody bound radioactive AVP+AVT;

C;

separating said antibody bound radioactive AVP+AVT, to be measured, from said free radioactive AVP+AVT;

D;

measuring the quantity of radioactive AVP+AVT selected from antibody bound radioactive AVP+AVT and free radioactive AVP+AVT;

E;

preparing a standard curve with known amounts of the AVP+AVT; and

F;

correlating the quantity of radioactive AVP+AVT measured with a known amount of said AVP+AVT read from said standard curve.

22. The method of claim 21 which includes:

quantifying by radioimmunoassay the level of AVP, whereby AVT levels are measurable as the difference between the AVP+AVT value and AVP value.